Breast Cancer Research and Treatment

, Volume 115, Issue 3, pp 437–452 | Cite as

Use of antioxidant supplements during breast cancer treatment: a comprehensive review

  • Heather Greenlee
  • Dawn L. Hershman
  • Judith S. Jacobson


Purpose An estimated 45–80% of breast cancer patients use antioxidant supplements after diagnosis, and use of antioxidant supplements during breast cancer treatment is common. Dietary supplements with antioxidant effects include vitamins, minerals, phytonutrients, and other natural products. We conducted a comprehensive review of literature on the associations between antioxidant supplement use during breast cancer treatment and patient outcomes. Methods Inclusion criteria were: two or more subjects; clinical trial or observational study design; use of antioxidant supplements (vitamin C, vitamin E, antioxidant combinations, multivitamins, glutamine, glutathione, melatonin, or soy isoflavones) during chemotherapy, radiation therapy, and/or hormonal therapy for breast cancer as exposures; treatment toxicities, tumor response, recurrence, or survival as outcomes. Results We identified 22 articles that met those criteria. Their findings did not support any conclusions regarding the effects of individual antioxidant supplements during conventional breast cancer treatment on toxicities, tumor response, recurrence, or survival. A few studies suggested that antioxidant supplements might decrease side effects associated with treatment, including vitamin E for hot flashes due to hormonal therapy and glutamine for oral mucositis during chemotherapy. Underpowered trials suggest that melatonin may enhance tumor response during treatment. Conclusion The evidence is currently insufficient to inform clinician and patient guidelines on the use of antioxidant supplements during breast cancer treatment. Thus, well designed clinical trials and observational studies are needed to determine the short- and long-term effects of such agents.


Breast cancer Antioxidant supplements Complementary and alternative medicine Chemotherapy Radiation therapy Hormonal therapy 



This work was supported by NCI Grant R25 CA09406 and the Lance Armstrong Foundation.


  1. 1.
    American Cancer Society (2008) Breast cancer facts & figures 2007–2008. Atlanta, American Cancer Society, IncGoogle Scholar
  2. 2.
    Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol 26:665–673CrossRefPubMedGoogle Scholar
  3. 3.
    Boon HS, Olatunde F, Zick SM (2007) Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 7:4CrossRefPubMedGoogle Scholar
  4. 4.
    Buettner C, Kroenke CH, Phillips RS et al (2006) Correlates of use of different types of complementary and alternative medicine by breast cancer survivors in the nurses’ health study. Breast Cancer Res Treat 100:219–227CrossRefPubMedGoogle Scholar
  5. 5.
    Henderson JW, Donatelle RJ (2004) Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med 10:52–57PubMedGoogle Scholar
  6. 6.
    Navo MA, Phan J, Vaughan C et al (2004) An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 22:671–677CrossRefPubMedGoogle Scholar
  7. 7.
    Ashikaga T, Bosompra K, O’Brien P et al (2002) Use of complimentary and alternative medicine by breast cancer patients: prevalence, patterns and communication with physicians. Support Care Cancer 10:542–548CrossRefPubMedGoogle Scholar
  8. 8.
    Lengacher CA, Bennett MP, Kip KE et al (2002) Frequency of use of complementary and alternative medicine in women with breast cancer. Oncol Nurs Forum 29:1445–1452CrossRefPubMedGoogle Scholar
  9. 9.
    Patterson RE, Neuhouser ML, Hedderson MM et al (2002) Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med 8:477–485CrossRefPubMedGoogle Scholar
  10. 10.
    Demark-Wahnefried W, Peterson B, McBride C et al (2000) Current health behaviors and readiness to pursue lifestyle changes among men and women diagnosed with early stage prostate and breast carcinomas. Cancer 88:674–684CrossRefPubMedGoogle Scholar
  11. 11.
    VandeCreek L, Rogers E, Lester J (1999) Use of alternative therapies among breast cancer outpatients compared with the general population. Altern Ther Health Med 5:71–76PubMedGoogle Scholar
  12. 12.
    Newman V, Rock CL, Faerber S et al (1998) Dietary supplement use by women at risk for breast cancer recurrence. The Women’s Healthy Eating and Living Study Group. J Am Diet Assoc 98:285–292CrossRefPubMedGoogle Scholar
  13. 13.
    Lawenda BD, Kelly KM, Ladas EJ et al (2008) Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 100:773–783. doi: 10.1093/jnci/djn148 CrossRefPubMedGoogle Scholar
  14. 14.
    D’Andrea GM (2005) Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 55:319–321CrossRefPubMedGoogle Scholar
  15. 15.
    Ladas EJ, Jacobson JS, Kennedy DD et al (2004) Antioxidants and cancer therapy: a systematic review. J Clin Oncol 22:517–528. doi: 10.1200/JCO.2004.03.086 CrossRefPubMedGoogle Scholar
  16. 16.
    Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol 26:665–673. doi: 10.1200/JCO.2007.13.5905 CrossRefPubMedGoogle Scholar
  17. 17.
    Weijl NI, Cleton FJ, Osanto S (1997) Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 23:209–240. doi: 10.1016/S0305-7372(97)90012-8 CrossRefPubMedGoogle Scholar
  18. 18.
    Hellman S (1993) Principles of radiation therapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 4th edn. J. B. Lippincott Co, PhiladelphiaGoogle Scholar
  19. 19.
    Sangeetha P, Das UN, Koratkar R et al (1990) Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. Free Radic Biol Med 8:15–19. doi: 10.1016/0891-5849(90)90139-A CrossRefPubMedGoogle Scholar
  20. 20.
    Conklin KA (2000) Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 37:1–18. doi: 10.1207/S15327914NC3701_1 CrossRefPubMedGoogle Scholar
  21. 21.
    Conklin KA (2004) Cancer chemotherapy and antioxidants. J Nutr 134:S3201–S3204Google Scholar
  22. 22.
    Borek C (2004) Dietary antioxidants and human cancer. Integr Cancer Ther 3:333–341. doi: 10.1177/1534735404270578 CrossRefPubMedGoogle Scholar
  23. 23.
    Simone CB II, Simone NL, Simone V et al (2007) Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 2. Altern Ther Health Med 13:40–47PubMedGoogle Scholar
  24. 24.
    Simone CB II, Simone NL, Simone V et al (2007) Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med 13:22–28PubMedGoogle Scholar
  25. 25.
    Labriola D, Livingston R (1999) Possible interactions between dietary antioxidants and chemotherapy. Oncology (Williston Park) 13:1003–1008 (discussion 1008, 1011-1002)Google Scholar
  26. 26.
    Moore HC, Green SJ, Gralow JR et al (2007) Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup Study 9623. J Clin Oncol 25:1677–1682. doi: 10.1200/JCO.2006.08.9383 CrossRefPubMedGoogle Scholar
  27. 27.
    Poulter JM, White WF, Dickerson JW (1984) Ascorbic acid supplementation and five year survival rates in women with early breast cancer. Acta Vitaminol Enzymol 6:175–182PubMedGoogle Scholar
  28. 28.
    Martin-Jimenez M, Diaz-Rubio E, Gonzalez Larriba JL et al (1986) Failure of high-dose tocopherol to prevent alopecia induced by doxorubicin. N Engl J Med 315:894–895PubMedGoogle Scholar
  29. 29.
    Perez JE, Macchiavelli M, Leone BA et al (1986) High-dose alpha-tocopherol as a preventive of doxorubicin-induced alopecia. Cancer Treat Rep 70:1213–1214PubMedGoogle Scholar
  30. 30.
    Weitzman SA, Lorell B, Carey RW et al (1980) Prospective study of tocopherol prophylaxis for anthracycline cardiac toxicity. Curr Ther Res 28:682–686Google Scholar
  31. 31.
    Legha SS, Wang YM, Mackay B et al (1982) Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann N Y Acad Sci 393:411–418. doi: 10.1111/j.1749-6632.1982.tb31279.x CrossRefPubMedGoogle Scholar
  32. 32.
    Lenzhofer R, Ganzinger U, Rameis H et al (1983) Acute cardiac toxicity in patients after doxorubicin treatment and the effect of combined tocopherol and nifedipine pretreatment. J Cancer Res Clin Oncol 106:143–147. doi: 10.1007/BF00395393 CrossRefPubMedGoogle Scholar
  33. 33.
    Barton DL, Loprinzi CL, Quella SK et al (1998) Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 16:495–500PubMedGoogle Scholar
  34. 34.
    Hoffer A, Pauling L (1990) Hardin Jones biostatistical analysis of mortality data for cohorts of cancer patients with a large fraction surviving at the termination of the study and a comparison of survival times of cancer patients receiving large regular oral doses of vitamin C and other nutrients with similar patients not receiving these doses. J Orthomol Med 5:143–154Google Scholar
  35. 35.
    Hoffer A, Pauling L (1993) Hardin Jones biostatistical analysis of mortality data for a second set of cohorts of cancer patients with a large fraction surviving at the termination of the study and a comparison of survival times of cancer patients receiving large regular oral doses of vitamin C and other nutrients with similar patients not receiving these doses. J Orthomol Med 8:157–167Google Scholar
  36. 36.
    Lockwood K, Moesgaard S, Hanioka T et al (1994) Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15:S231–S240. doi: 10.1016/0098-2997(94)90033-7 CrossRefPubMedGoogle Scholar
  37. 37.
    Lesperance ML, Olivotto IA, Forde N et al (2002) Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study. Breast Cancer Res Treat 76:137–143. doi: 10.1023/A:1020552501345 CrossRefPubMedGoogle Scholar
  38. 38.
    Premkumar VG, Yuvaraj S, Vijayasarathy K et al (2007) Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy. Biol Pharm Bull 30:367–370. doi: 10.1248/bpb.30.367 CrossRefPubMedGoogle Scholar
  39. 39.
    de Souza Fede AB, Bensi CG, Trufelli DC et al (2007) Multivitamins do not improve radiation therapy-related fatigue: results of a double-blind randomized crossover trial. Am J Clin Oncol 30:432–436. doi: 10.1097/COC.0b013e31804b40d9 CrossRefPubMedGoogle Scholar
  40. 40.
    Li Y, Yu Z, Liu F et al (2006) Oral glutamine ameliorates chemotherapy-induced changes of intestinal permeability and does not interfere with the antitumor effect of chemotherapy in patients with breast cancer: a prospective randomized trial. Tumori 92:396–401PubMedGoogle Scholar
  41. 41.
    Peterson DE, Jones JB, Petit RGII (2007) Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 109:322–331. doi: 10.1002/cncr.22384 CrossRefPubMedGoogle Scholar
  42. 42.
    Nobile MT, Vidili MG, Benasso M et al (1989) A preliminary clinical study of cyclophosphamide with reduced glutathione as uroprotector. Tumori 75:257–258PubMedGoogle Scholar
  43. 43.
    Lissoni P, Tancini G, Paolorossi F et al (1999) Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. J Pineal Res 26:169–173. doi: 10.1111/j.1600-079X.1999.tb00579.x CrossRefPubMedGoogle Scholar
  44. 44.
    Lissoni P, Barni S, Mandala M et al (1999) Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 35:1688–1692. doi: 10.1016/S0959-8049(99)00159-8 CrossRefPubMedGoogle Scholar
  45. 45.
    Lissoni P, Barni S, Meregalli S et al (1995) Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 71:854–856PubMedGoogle Scholar
  46. 46.
    Quella SK, Loprinzi CL, Barton DL et al (2000) Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 18:1068–1074PubMedGoogle Scholar
  47. 47.
    Van Patten CL, Olivotto IA, Chambers GK et al (2002) Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 20:1449–1455. doi: 10.1200/JCO.20.6.1449 CrossRefPubMedGoogle Scholar
  48. 48.
    MacGregor CA, Canney PA, Patterson G et al (2005) A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer 41:708–714. doi: 10.1016/j.ejca.2005.01.005 CrossRefPubMedGoogle Scholar
  49. 49.
    Block KI, Koch AC, Mead MN et al (2008) Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 123:1227–1239. doi: 10.1002/ijc.23754 CrossRefPubMedGoogle Scholar
  50. 50.
    Bairati I, Meyer F, Gelinas M et al (2005) Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol 23:5805–5813. doi: 10.1200/JCO.2005.05.514 CrossRefPubMedGoogle Scholar
  51. 51.
    Bairati I, Meyer F, Gelinas M et al (2005) A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 97:481–488PubMedCrossRefGoogle Scholar
  52. 52.
    Kwan ML, Ambrosone CB, Lee MM et al (2008) The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California. Cancer Causes Control. doi: 10.1007/s10552-008-9170-5 Google Scholar
  53. 53.
    Greenlee H, Kwan ML, Krathwohl SE et al (2008) History of CAM use in a prospective breast cancer cohort study. In: Presented at 4th biennial cancer survivorship research conference, 18–20 June 2008, Atlanta, GA (abstr 1794)Google Scholar
  54. 54.
    Greenlee H, Gammon MD, Abrahamson PE et al (2007) Use of supplemental antioxidants after breast cancer diagnosis and during breast cancer treatment among women with breast cancer in the Long Island Breast Cancer Study Project. In: Presented at society for integrative oncology 4th international conference, 15–17 November 2007, San Francisco CA (abstr 18157)Google Scholar
  55. 55.
    Albanes D, Heinonen OP, Huttunen JK et al (1995) Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 62:1427S–1430SPubMedGoogle Scholar
  56. 56.
    Omenn GS, Goodman GE, Thornquist MD et al (1996) Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88:1550–1559. doi: 10.1093/jnci/88.21.1550 CrossRefPubMedGoogle Scholar
  57. 57.
    van Dalen EC, Caron HN, Dickinson HO et al (2008) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2:CD003917PubMedGoogle Scholar
  58. 58.
    Savarese DM, Savy G, Vahdat L et al (2003) Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 29:501–513. doi: 10.1016/S0305-7372(03)00133-6 CrossRefPubMedGoogle Scholar
  59. 59.
    Lissoni P (2007) Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris) 55:201–204. doi: 10.1016/j.patbio.2006.12.025 Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Heather Greenlee
    • 1
    • 2
  • Dawn L. Hershman
    • 1
    • 2
    • 3
  • Judith S. Jacobson
    • 1
    • 2
  1. 1.Department of Epidemiology, Mailman School of Public HealthColumbia UniversityNew YorkUSA
  2. 2.Herbert Irving Comprehensive Cancer CenterColumbia UniversityNew YorkUSA
  3. 3.Department of Medicine, College of Physicians and SurgeonsColumbia UniversityNew YorkUSA

Personalised recommendations